Built to serve two audiences at once: clinicians and researchers
Earlier detection means earlier treatment — but only if the signal is trustworthy enough for a clinic, and open enough for a research lab to build on.
Shift from crisis response to preventive care
Catch biological risk signals years before symptoms appearMoves care ahead of the 10+ year average diagnostic delay.
Stratify patients for NDD clinical trialsAddresses one of the leading causes of the >90% CNS trial failure rate.
Give families an actual answer at diagnosisReplaces "we don't know" with a quantified, evidence-based risk signal.
Interpretable biology, not another black box
Ranked, explainable biomarkersEvery output traces back to specific genes and pathways — built for publication, not just prediction.
Human-relevant models where animal studies fall shortiPSC-derived neurons capture human-specific NDD variability that mouse models miss.
Functional data DNA-only tests can't seeCaptures how a variant actually behaves in a living neuronal system — modifier genes and all.
Aligned with the direction the field is already moving
The scientific case for precision psychiatry and biomarker-informed mental health care already has substantial institutional backing across the EU — a meaningful tailwind for a Berlin-based venture in this space.
- German Center for Mental Health — a Munich/Augsburg-based consortium explicitly focused on precision approaches in psychiatry, bringing together psychiatry, genomics, and computational biology researchers.
- ECNP Precision Psychiatry Roadmap — the European College of Neuropsychopharmacology's initiative, including a dedicated expert meeting in Frankfurt on biomarker identification, validation, and clinical implementation.
- PROPSY (France) — a five-year national program explicitly focused on discovering prognostic and stratification biomarkers for bipolar disorder, major depressive disorder, schizophrenia, and autism spectrum disorder.
- IMI PRISM & PRISM2 — the EU's Innovative Medicines Initiative projects exploring shared biological signatures of social dysfunction across dementia, schizophrenia, and depression.
This landscape suggests a research and policy environment already primed to recognize the value of a biology-informed, penetrance-aware approach — but it also means credibility with this community, through publication, collaboration, or advisory relationships, will matter as much as commercial traction in the earliest years.
The regulatory pathway is real — and already proven achievable
Any product that reports a risk score to a clinician in the EU falls under the In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR), fully in effect since May 2022. Biomarker-based risk-stratification tools of this kind are generally expected to fall into Class C — moderate-to-high public health risk — requiring Notified Body involvement and robust clinical evidence covering scientific validity, analytical performance, and clinical performance.
Critically, this pathway is proven, not theoretical: NeuroKaire's directly comparable iPSC-plus-AI psychiatric tool received CE-IVD marking in October 2022 — European regulators are already willing to certify this category of product. In December 2025, the European Commission proposed targeted amendments to IVDR, including priority review pathways for "breakthrough" and "orphan" diagnostics — potentially favorable for a rare-disease-adjacent, novel biomarker product like this, though not yet finalized law.
Practical implication: IVDR compliance is typically a multi-year, capital-intensive process. It's budgeted for explicitly in the milestone and fundraising plan — not treated as a late-stage afterthought.